Simultaneous inhibition of the constitutively activated nuclear factor κB and of the Interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells

Cell Cycle

Volumn 7, Issue 20, 2008, Pages 3235-3245

  Malara, Natalia ^a   Focà, Domenico ^a   Casadonte, Francesca ^a   Sesto, Maria Francesca ^a   Macrina, Lorenza ^a   Santoro, Lucia ^a   Scaramuzzino, Monica ^a   Terracciano, Rosa ^a   Savino, Rocco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Adenoviral vector; Apoptosis; IL 6; Multiple myeloma; NF B; Signal transduction; U266

Indexed keywords

ADENOVIRUS VECTOR; BORTEZOMIB; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTAGONIST SANT7; INTERLEUKIN 6 RECEPTOR; PHOSPHOPROTEIN; PROTEASOME; RECEPTOR BLOCKING AGENT; STAT3 PROTEIN; UNCLASSIFIED DRUG; WEDELOLACTONE; WITHAFERIN A;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 54049149951     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.20.6832     Document Type: Article

References (40)

1. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumour cells to chemotherapeutic agents. Clin Cancer Res 2003; 9:1136-44.
2. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NFkappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999; 93:3044-52.
3. Chauhan D, Anderson KC. Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis 2003; 8:337-43.
4. Gilmore TD. The Rel/NFkappaB signal transduction pathway: introduction. Oncogene 1999; 18:6842-4.
5. Masdehors P, Omura S, Merle-Beral H, Mentz F, Cosset JM, Dumont J, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999; 105:752-7.
6. Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 1998; 95:2727-30.
7. Goldberg AL, Rock K. Not just research tools: proteasome inhibitors offer therapeutic promise. Nat Med 2002; 8:338-40.
8. Lee JC, Peter ME. Regulation of apoptosis by ubiquitination. Immunol Rev 2003; 193:39-47.
9. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001; 116:637-46.
10. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4:349-60.
11. Jobin C, Panja A, Hellerbrand C, Iimuro Y, Didonato J, Brenner DA, et al. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol 1998; 160:410-8.
12. Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, et al. Analysis of expression of nuclear factor kappaB (NFkappaB) in multiple myeloma: downregulation of NFkappaB induces apoptosis. Br J Haematol 2001; 115:279-86.
13. 2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection. Gene Ther 1999; 6:1054-63.
14. Imperiale MJ, Kochanek S. Adenovirus vectors: biology, design and production. Curr Top Microbiol Immunol 2004; 273:335-57.
15. Maione D, Wiznerowicz M, Delmastro P, Cortese R, Ciliberto G, La Monica N, et al. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther 1998; 11:859-68.
16. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100:194-9.
17. Juge-Morineau N, Harousseau JL, Amiot M, Bataille R. The Retinoblastoma susceptibility gene RB-1 in multiple myeloma. Leuk Lymphoma 1997; 24:229-37.
18. Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G. Deletion of the retinoblastoma gene in multiple myeloma. Leukemia 1994; 8:1280-4.
19. Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet C, et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992; 7:1015-8.
20. + cells derived from multiple myeloma patients and suppression of these transcription factors leads to apoptosis. Blood 2004; 103: 3175-84.
21. Tu Y, Xu FH, Liu J, Vescio R, Berenson J, Fady C, Lichtenstein A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide and hydrogen peroxide. Blood 1996; 88:1805-12.
22. Demartis A, Bernassola F, Savino R, Melino G, Ciliberto G. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res 1996; 56:4213-8.
23. Sandig V, Youil R, Bett AJ, Franlin LL, Maione D, Oshima M, et al. Optimization of the Helper Dependent Adenovirus System for Production and Potency in vivo. Proc Natl Acad Sci USA 2000; 97:1002-7.
24. Richardson PG, Hideshima T, Mitsiades C, Anderson KC. The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw 2007; 5:149-6.
25. Facon T, Avert-Loiseau H, Guillerm G, Moreau P, Genebieve F, Zandeki M. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy Blood 2001; 97:1566-71.
26. Dalton WS, Bergsagel LP, Kuehl WM, Anderson KC, Harousseau JL. Multiple Myeloma. Hematology Am Soc Hematol Educ Program 2001; 157-77.
27. Zhou P, Kalakonda N, Comenzo RL. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol 2005; 128:636-44.
28. Gabrea A, Bergsagel PL, Chesi M, Shou Y, Kuehl WM. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell 1999; 3:119-23.
29. Pratt G, Fenton JA, Davies FE, Rawstron AC, Richards SJ, Collins JE, et al. Insertional events as well as translocations may arise during aberrant immunoglobulin switch recombination in a patient with multiple myeloma. Br J Haematol 2001; 112:388-91.
30. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bachelerie F, Thomas D, Hay RT. Inducible nuclear expression of newly synthesized IkappaB alpha negatively regulates DNA-binding and transcriptional activities of NFkappaB. Mol Cell Biol 1995; 15:2689-96.
31. Malek S, Huxford T, Ghosh G. IkappaBalpha functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NFkappaB. J Biol Chem 1998; 273:25427-35.
32. Rowley M, Liu P, Van Ness B. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin and melphalan. Blood 2000; 96:3175-80.
33. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, Anderson KC. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159:2212-21.
34. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Munshi N, et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem 2003; 278:17593-6.
35. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 2000; 275:322-7.
36. Ito Y, Mishra NC, Yoshida K, Kharbanda S, Saxena S, Kufe D. Mitochondrial targeting of JNK/SAPK in the phorbol ester response of myeloid leukemia cells. Cell Death Differ 2001; 8:794-800.
37. Horbinski C, Chu CT. Kinase signaling cascades in the mitochondrion: a matter of life or death. Free Radic Biol Med 2005; 38:2-11.
38. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NFkappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19:5923-9.
39. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997; 89:227-34.
40. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer biding proteins with "mini extracts" prepared from a small number of cells. Nucleic Acid Res 1989; 17:6419.